Abstract: Methods of treating or preventing cancer, diabetes, and/or obesity in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of an SLC25A1 inhibitor as described herein. Also provided herein are pharmaceutical compositions comprising an SLC25A1 inhibitor and a chemotherapeutic agent. Further provided herein are methods of inhibiting SLC25A1 in a cell.

Abstract: Methods of determining if a subject has an increased risk of poor recovery after suffering a stroke and methods of treating a subject recovering from a stroke. The methods comprise analyzing at least one plasma sample taken from the subject to assess a microRNA (miRNA) profile of the subject and comparing the subject's miRNA profile with a normal miRNA profile, to determine if the subject's miRNA profile is altered compared to a normal miRNA profile. An alteration of the subject's miRNA profile is indicative that the subject has an increased risk of poor recovery after suffering a stroke.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing the gene expression profile from peripheral blood leukocytes taken from the subject and comparing the value of the subject's gene expression profile with the value of a normal gene expression profile. A change in the value of the subject's gene expression profile, above or below normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: Disclosed are methods of treating anxiety or depression, comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP), 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and pharmaceutically acceptable salts thereof.

Abstract: Provided herein is a method of determining a level of one or more miRNAs in a subject that has or is at risk of developing Gulf War Illness (GWI). The method includes obtaining a biological sample from the subject and determining a level of one or more miRNA molecules in the biological sample. Also provided are compositions and kits for carrying out the provided methods.

Abstract: A non-invasive system, and method for simple, quantitative screening for mTBI and other forms of mid cognitive impairment using a visuo-motor performance test (for example, a submaximal grip test) in response to visual feedback to quantitatively measure the intra-individual variability of performance metric for initial screening of patients with mild traumatic brain injury (mTBI), and other neurological disorders. The system and method can be administered in minutes, by any level of caregiver, in any environment including military in-the-field or sports on-field deployments, and is useful in screening those truly injured from those disguising or mimicking injury. In addition to screening, the system and method can be used to monitor and/or detect changes to intra-individual variability over time by comparison to a baseline, which in turn is helpful in determining estimated recovery trajectory or other related information.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present application provides methods of preventing and treating the toxic effects of exposure to organophosphate agents. In embodiments, targeted cationic liposome complexes delivering nucleic acid molecules encoding butyrylcholinesterase and a polyproline rich peptide are administered. Suitably, the administration is via inhalation or via aerosol. Also provided are cationic liposome complexes and methods of making the complexes for such administration.

Abstract: Monitoring systems and methods for tracking movement of one or more animals in an enclosure, such as a fish tank, include introducing various stimuli, such as food, light, and auditory stimuli, and tracking the movement of the animals in response to these stimuli. Movement patterns of the animals can be determined and analyzed from data obtain from cameras that record images/videos of the relevant portions of the enclosure.

Abstract: Provided are electrocatalysts, fuel cells, methods of making fuel cells, and methods of generating an electric current, each featuring a platinum (Pt)-containing substrate in contact with an aqueous solution comprising Pb2+. Electrocatalysts of the invention are formed via underpotential deposition (UPD) when a trace amount of Pb2+ is present in the electrolyte of a half anodic cell for oxidizing formic acid using Pt as the anode. Surprisingly, the UPD process dramatically enhances the activity of formic acid oxidation, at least as much as 10-fold compared with palladium (Pd) black. In an embodiment, the electrocatalyst comprises a Pt-containing substrate, a submonolayer of lead (Pb) adsorbed onto the Pt-containing substrate, and an aqueous solution comprising Pb2+, wherein the concentration of Pb2+ in the aqueous solution is 10 to 500 ?m.

Abstract: Provided are methods and devices useful for treating a respiratory disease or disorder involving the central or upper airways. The methods and devices deliver to central or upper airways of a subject a vapor or aerosol comprising an effective amount of an active ingredient selected from the group consisting of menthol, menthone, neomenthol, isomenthol, and menthofuran. The methods are useful for treating conditions including cough, asthma, bronchitis, and allergic rhinitis.

Abstract: The present invention is directed to a platform (e.g., Web-based) that enables basic and clinical research activities by integrating patient characteristics and clinical outcome data with a variety of high-throughput research data in a unified environment. While several rich data repositories for high dimensional research data exist in the public domain, most focus on a single data type and do not support integration across multiple technologies. The present invention in at least one embodiment includes a broad collection of bioinformatics and systems biology tools for analysis and visualization of four major “omics” types: DNA, mRNA, microRNA, and metabolites, as well as next-generation sequencing. The present invention helps facilitate systems medicine by providing easy identification of trends and patterns in integrated datasets and hence facilitate the use of better targeted therapies for cancer.

Abstract: A system and method involves detecting operational social disruptive events on a global scale, modeling data in conjunction with linguistics analysis to establish responsive actions, and generating visualization and executing models for communicating information.

Abstract: Embodiments of the present systems and methods may provide techniques for two-factor authentication (2FA) that leverage voice assistant devices such as Google Home and Amazon Echo. For example, in an embodiment, a computer-implemented method of authentication may comprise receiving an authentication request for a user of a service, authenticating the user using two-factor authentication, wherein at least one factor of the two-factor authentication is audio, and validating the authentication request upon validation of both factors of the two-factor authentication.

Abstract: Cavitand compositions that comprise void spaces are disclosed. The void spaces may be empty, which means that voids are free of guest molecules or atoms, or the void spaces may comprise guest molecules or atoms that are normally in their gas phase at standard temperature and pressure. These cavitands may be useful for industrial applications, such as the separation or storage of gasses. Novel cavitand compounds are also disclosed.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: A system for producing dry nanoparticles from a liquid includes a closed tubing system which incorporates a mister, heater and an electrostatic collector therein. The system is able to produce dry nanoparticles from liquid-suspensions and from solvent solutions.

Abstract: Monitoring systems and methods for tracking movement of one or more animals in an enclosure, such as a fish tank, include introducing various stimuli, such as food, light, and auditory stimuli, and tracking the movement of the animals in response to these stimuli. Movement patterns of the animals can be determined and analyzed from data obtain from cameras that record images/videos of the relevant portions of the enclosure.

Abstract: A system for determining the presence of cell-free non-coding RNA (cfNCR) biomarkers in interstitial fluid includes a microfluidic device for non-invasively and passively accessing interstitial fluid from a patient. The microfluidic device is formed of a substrate containing multiple vertical micro channels therethrough, wherein at a first end of each of the multiple vertical micro channels a microheater is formed for controllably ablating a portion of dry dead skin cells to access the interstitial fluid; and wherein at a second end of each of the multiple vertical micro channels is a horizontal micro channel for receiving accessed interstitial fluid from a vertical micro channel and guiding the accessed interstitial fluid to a common collection port.